ISTH 2021

2021-07-17 - 2021-07-21
Online, Virtual

EHA 2021

2021-06-09 - 2021-06-17
Online, Virtual

ASH 2020

2020-12-05 - 2020-12-08
Online, Virtual

EHA 2020

2020-06-11 - 2020-06-21
Online, Virtual

ESH 2020

2020-05-29 - 2020-06-01
Online, Virtual

ASH 2019

2019-12-07 - 2019-12-10
Orlando, United States

EHA 2019

2019-06-13 - 2019-06-16
Amsterdam, Netherlands

EMMA 2019

2019-01-31 - 2019-02-02
Vienna, Austria

ASH 2018

2018-12-01 - 2018-12-04
San Diego, United States
Search in Scientific Content:
Date
Filters:
Abelacimab
13:53

Abelacimab for Prevention of Venous Thromboembolism

Presenter: Jeffrey Weitz
ISTH 2021
The QUAZAR
13:56

The QUAZAR AML-001 Maintenance Trial

Presenter: Eytan Stein
EHA 2021
Idecabtage...
10:25

Idecabtagene vicleucel, a BCMA-​directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma

Presenter: Albert Oriol
EHA 2021
Novelties
7:52

Novelties in the treatment of Multiple Myeloma

Presenter: Enrique Ocio
EHA 2021
Treatment
9:31

Treatment of hematological malignancies in 2021

Presenter: Paolo Corradini
EHA 2021
Novelties
10:59

Novelties in the treatment of chronic myeloid leukemia

Presenter: Giuseppe Saglio
EHA 2021
Novelties
13:14

Novelties in the treatment of follicular lymphoma

Presenter: Kai Hübel
EHA 2021
Harnessing
10:06

Harnessing the immune system in multiple myeloma: CAR T-cell therapy and bispecific antibodies

Presenter: Xavier Leleu
EHA 2021
Results fr
5:00

Results from the JAKARTA and JAKARTA2 trials

Presenter: Claire Harrison
EHA 2021
Novelties
8:56

Novelties on the treatment of Multiple Myeloma

Presenter: Mohamad Mohty
EHA 2021
Effect of
4:54

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

Presenter: John Kuruvilla
ASH 2020
Optimal Du
3:55

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Presenter: Dennis Kim
ASH 2020
Novelties
8:45

Novelties on the treatment of Multiple Myeloma and Plasma Cell Disorders

Presenter: Joseph Mikhael
ASH 2020
Comprehens
14:08

Comprehensive summary of novel multiple myeloma data from ASH2020

Presenter: Andrzej Jakubowiak
ASH 2020
Comparison
7:32

Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

Presenter: Amer Zeidan
ASH 2020
Polatuzuma
5:05

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Presenter: Giuseppe Gritti
ASH 2020
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Perioperat
7:20

Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant

Presenter: James Douketis
Safety and
12:01

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Presenter: Franco Locatelli
A Randomiz
5:32

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Presenter: Tait D. Shanafelt
Phase 3 Ra
6:37

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Presenter: Thierry Facon
Acquisitio
5:45

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Presenter: Piers Blombery
Best of AS
39:04

Best of ASH

Presenter: John D. Crispino
Long Term
5:48

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

Presenter: Corinne Summers
A Personal
6:14

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes

Presenter: Aziz Nazha
Initial Re
6:41

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Presenter: Amy Burd
Multicente
8:43

Multicenter Microbiota Analysis Indicates That Pre-HCT Microbiota Injury Is Prevalent across Geography and Predicts Poor Overall Survival

Presenter: Jonathan U. Peled
Rivaroxaba
11:08

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

Presenter: Alok A. Khorana